Observational studyIndian journal of pediatrics2026
Serum Soluble Programmed Death Ligand-1 (sPD-L1) as a Diagnostic Marker in Neonatal Sepsis.
Observational study in Indian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum Soluble Programmed Death Ligand-1 (sPD-L1) as a Diagnostic Marker in Neonatal Sepsis: Correspondence.Indian journal of pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate serum soluble programmed death ligand-1 (sPD-L1) levels in neonatal sepsis and assess its diagnostic performance, association with disease severity, and clinical outcomes.
methodsThis prospective observational study was conducted in a tertiary-care neonatal intensive care unit. Neonates with suspected sepsis, defined according to National Neonatology Forum (NNF) 2021 guidelines, were enrolled after parental consent. Serum sPD-L1 levels were measured using enzyme-linked immunosorbent assay (ELISA). Comparisons were performed across early-onset and late-onset sepsis, culture-positive and culture-negative sepsis, presence of multi-organ dysfunction syndrome (MODS), and survival outcomes. Receiver operating characteristic (ROC) curve analysis was used to determine diagnostic accuracy.
resultsSerum sPD-L1 levels were significantly elevated in neonates with sepsis. Higher levels were observed in early-onset sepsis, culture-positive sepsis, neonates with MODS, and non-survivors, indicating a positive association with disease severity and adverse outcomes. ROC analysis demonstrated good diagnostic performance, with an area under the curve of 0.86. A cut-off value of 85 pg/mL showed clinically meaningful diagnostic discrimination.
conclusionsSerum sPD-L1 is significantly elevated in neonatal sepsis and correlates with severity, organ dysfunction, and mortality. It may serve as a promising adjunct biomarker for early diagnosis and risk stratification in neonatal sepsis, warranting validation in larger multicentric studies.
Indexed as
Identifiers
42258041What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.